Microba Life Sciences Limited (AU:MAP)
ASX:MAP
Top Page
Microba Life Sciences Limited
(Sydney:MAP)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.07
▼(-13.75% Downside)
Action:ReiteratedDate:01/17/26
The score is primarily constrained by weak financial performance, including falling revenue and persistent losses with negative operating cash flow. Technical indicators are comparatively supportive (price above key moving averages and positive MACD), but valuation is difficult to assess given the negative P/E and no dividend data.
Positive Factors
Low leverage
A debt-to-equity ratio of 0.10 signals low financial leverage and reduced refinancing pressure. Over the next 2-6 months this provides balance-sheet flexibility to fund R&D, lab capacity or absorb revenue volatility without immediate heavy debt servicing constraints.
Negative Factors
Declining revenue
A reported 24.28% revenue decline reflects weakening top-line momentum and reduces leverage to cover fixed lab and R&D costs. Continued contraction erodes scale economics, limits reinvestment capacity and forces trade-offs between growth initiatives and cost containment.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
A debt-to-equity ratio of 0.10 signals low financial leverage and reduced refinancing pressure. Over the next 2-6 months this provides balance-sheet flexibility to fund R&D, lab capacity or absorb revenue volatility without immediate heavy debt servicing constraints.
Read all positive factors
Microba Life Sciences Limited (MAP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$42.02M
Dividend YieldN/A
Average Volume (3M)469.77K
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue Growth29.60%
EPS Growth33.00%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding608,963,000
10 Day Avg. Volume548,444
30 Day Avg. Volume469,774
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.17
Price to Sales (P/S)2.43
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.21Price Target Upside162.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$18.83M
Microba Life Sciences Limited Business Overview & Revenue Model
Company Description
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pat...
How the Company Makes Money
Microba Life Sciences makes money primarily by selling microbiome-related products and services. Key revenue streams include: (1) consumer- and clinician-facing gut microbiome tests, where the company earns revenue per test sold (typically includi...
Microba Life Sciences Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.90M | 15.67M | 12.09M | 5.42M | 4.69M | 3.73M |
| Gross Profit | -2.96M | 7.44M | 5.91M | -6.77M | 2.37M | -5.30M |
| EBITDA | -21.64M | -10.51M | -17.10M | -17.07M | -9.86M | -6.28M |
| Net Income | -19.75M | -14.94M | -19.94M | -12.68M | -11.47M | -7.52M |
Balance Sheet | ||||||
| Total Assets | 43.35M | 47.44M | 58.04M | 46.95M | 39.48M | 18.49M |
| Cash, Cash Equivalents and Short-Term Investments | 11.27M | 11.74M | 20.89M | 32.04M | 30.79M | 13.03M |
| Total Debt | 3.31M | 3.23M | 1.58M | 1.14M | 1.33M | 269.02K |
| Total Liabilities | 12.27M | 14.94M | 16.82M | 8.23M | 5.94M | 3.55M |
| Stockholders Equity | 30.18M | 32.49M | 41.22M | 38.57M | 33.54M | 14.94M |
Cash Flow | ||||||
| Free Cash Flow | -15.38M | -14.91M | -19.95M | -15.43M | -12.32M | -7.85M |
| Operating Cash Flow | -15.05M | -12.01M | -15.57M | -12.39M | -10.45M | -7.18M |
| Investing Cash Flow | -3.39M | -2.83M | -13.95M | -3.00M | -1.73M | -522.48K |
| Financing Cash Flow | 12.34M | 5.58M | 18.39M | 16.68M | 29.22M | 13.84M |
Microba Life Sciences Limited Technical Analysis
Negative
0.08
Price Trends
0.08
Negative
0.08
Negative
0.08
Negative
Market Momentum
>-0.01
Positive
38.65
Neutral
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MAP, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.65 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MAP.
Microba Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$53.20M | 10.72 | 72.82% | ― | 11.93% | 2.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$42.02M | -1.06 | -63.04% | ― | 29.60% | 33.00% | |
46 Neutral | AU$168.57M | -7.39 | -164.12% | ― | 12.96% | 40.81% | |
42 Neutral | AU$33.18M | -2.45 | -164.22% | ― | ― | 23.85% | |
41 Neutral | AU$18.17M | -2.23 | -23.93% | ― | 62.81% | 16.37% | |
38 Underperform | AU$49.98M | -3.02 | -37.14% | ― | 2.33% | 12.50% |
* Healthcare Sector Average
AU:MAP
Microba Life Sciences Limited
0.07
-0.11
-61.67%
AU:BDX
BCAL Diagnostics Limited
0.09
-0.01
-10.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.21
0.19
950.00%
AU:CTE
Cryosite Limited
1.09
0.30
37.97%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.32
-80.00%
AU:IIQ
Inoviq Ltd
0.36
-0.03
-6.58%
Microba Life Sciences Limited Corporate Events
Microba boosts core microbiome testing as it exits legacy products and targets FY26 break-even
Feb 25, 2026
Microba Life Sciences reported strong operational progress for the half year to 31 December 2025, with 10,258 core tests sold globally, a 113% increase on the prior period, and an annualised run rate above 21,300 tests as it targets more than 24,0...
Microba Launches Q2 FY26 Investor Webinar and Expands Interactive Investor Hub
Jan 29, 2026
Microba Life Sciences has released its Q2 FY26 investor presentation and scheduled a quarterly investor webinar to be hosted by CEO Dr Luke Reid on 29 January 2026, offering investors a detailed update on the company’s performance and activi...
Microba to Release Q2 FY26 Report and Host Investor Webinar
Jan 21, 2026
Microba Life Sciences Limited has announced it will release its Q2 FY26 Quarterly Activities Report, cash flow statement and investor presentation on 29 January 2026, alongside hosting a quarterly investor webinar presented by CEO Dr Luke Reid. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.